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Abstract
C9ORF72 repeat expansion is the most frequent causal genetic mutation giving rise to
amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD). The relatively recent
discovery of the C9ORF72 repeat expansion in 2011 and the complexity of the mutation have
meant that animal models that successfully recapitulate human C9ORF72 repeat expansion-
mediated disease are only now emerging. Concurrent advances in the use of patient-derived
induced pluripotent stem cells (iPSCs) to model aspects of neurological disease offers an
additional approach for the study of C9ORF72 mutation. This review focuses on the
opportunities of human C9ORF72 iPSC platforms to model pathological aspects of disease and
how ﬁndings compare with other existing models of disease and post mortem data.
INTRODUCTION
Expansion of a GGGGCC (G4C2) intronic hexanucleotide in the
C9ORF72 (chromosome 9, open reading frame 72) gene is the
most common cause of familial ALS and accounts for 10% of
sporadic ALS (1, 59, 68). The C9ORF72 repeat expansion
(C9ORF72RE) is also the most frequent underlying genetic cause of
FTD (12, 59) and approximately 50% of ALS patients co-present
with FTD (57). Typically, the number of repeats in healthy individ-
uals is lower than 30 and of several hundred repeats in affected
individuals. Cytoplasmic TDP-43 inclusions and C9ORF72RE
RNA foci are major histopathological features of both ALS and
FTD (12, 45, 52). The pathogenicity of the C9ORF72RE mutation
may act through two potential mechanisms; 1) a loss of function
generated through haploinsufﬁciency of the C9ORF72 gene, and 2)
a gain of function mediated through transcribed and/or translated
elements of the mutant intronic repeat expansion (74).
A range of animal and cellular models have been developed to
understand the cellular perturbations generated by the C9ORF72RE.
Valuable insights into C9ORF72RE-mediated disease have been
determined using animal models, which include C. elegans, zebra-
ﬁsh, drosophila and mice; collectively these reveal the complexity
of potential disease mechanism (see (46) for a review). Indeed, the
absence of TDP-43 inclusions, RNA foci and neurodegeneration in
C9orf72 knock out mice (31) have demonstrated that loss of
function is insufﬁcient to generate disease though may contribute
to an inﬂammatory component of the disease (55, 71). In contrast,
C9ORF72RE mouse models that support a gain of function mecha-
nism and successfully exhibit neurodegeneration with pathological
hallmarks of C9ORF72RE-mediated disease have only recently
been developed (7, 38). Such genetically engineered models that
follow past strategies that generated only partial recapitulation of
the C9ORF72RE phenotype will undoubtedly generate important
future insights. Animal models are reviewed elsewhere (46, 74).
Conversely, iPSC technology now allows the derivation of cell-
type speciﬁc and regionally-deﬁned material that harbors the
patient genetic background. This also allows to recapitulate the dis-
ease in physiological context wherein the mutation is expressed in
physiological level. Concurrently, recent development of CRISPR/
Cas9 mediated genome editing has paved a way to generate iso-
genic iPSC lines. This has allowed to study the role of mutation in
a genetically deﬁned manner and overcome the challenges of
genetic variability between different iPSC lines (61). In this regard
multiple studies on a range of C9ORF72RE patient iPSC-derived
cell types including motor neurons, cortical neurons, astrocytes and
oligodendrocytes have been already performed. Beyond recapitulat-
ing major pathological signatures of disease, iPSC-based platforms
have yielded novel biochemical and physiological information pre-
viously unknown in the context of C9ORF72RE. In this review we
will highlight how this technology has contributed to our under-
standing of C9ORF72RE-mediated disease.
C9ORF72 protein and loss of function
hypothesis
The C9ORF72 gene generates three different mRNA transcript var-
iants (V1, V2, V3). Transcript variant 1 and 2 contain the repeat
expansion mutation in the ﬁrst intron therefore pre-mRNA form V1
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and V2 contains the G4C2 repeats, whereas transcriptional start site
for variant 2 is after the repeat expansion mutation. Transcript V1
encodes for a short isoform of C9ORF72 protein, whereas tran-
script V2 and V3 encode for the long isoform of C9ORF72 protein.
Although the structure of C9ORF72 protein is not yet elucidated, it
is predicted to be related to differentially expressed in normal
and neoplasia (DENN) protein which functions as a GDP/GTP
exchange factor (GEF) in activating RAB GTPases (36). Localiza-
tion studies in human post-mortem tissues suggested that
C9ORF72 short isoform is localized in the nuclear membrane inter-
acting with components of nuclear pore complex and C9ORF72
long isoform is localized in the cytoplasm (83). Consistent with
this prediction, C9ORF72 has been reported to associate with Rab
proteins and thus involved in the regulation of endocytosis and
autophagy (17). Earlier expression study in mouse showed
C9ORF72 is highly expressed in neuronal cells (73). However,
recent studies have observed highest levels of C9ORF72 expression
in microglia and C9ORF72 knock out leads to an altered auto-
immune response with age related neuroinﬂammation leading to
progressive splenomegaly and lymphadenopathy in mice (55).
Hypothesis of C9ORF72 haploinsufﬁciency leading to neurode-
generation was explored based on the observation of reduced
C9ORF72 transcripts (V1, V2, V3) in patient tissues and iPSC-
derived neurons (1, 12, 16). Reduced expression of C9ORF72 is
attributed to CpG hypermethylaion of promoter (37) and repeat
expansion mutation binding to trimethylated H3K9 and H3K27
leading to epigenetic silencing (4). A number of in-vitro studies
using mouse primary neurons have shown that C9ORF72 interacts
with Rab proteins and loss of C9ORF72 increases levels of p62
and positively regulates autophagy in the spleen and liver (72, 79).
Interestingly, studies have observed increased level of p62, an
autophagy marker, in post-mortem tissues and motor neurons
derived from C9ORF72 iPSC. Conversely, treatment with chloro-
quine (autophagy inducer) increased the vulnerability of iPSC-
derived C9ORF72 motor neurons to autophagy (1). Recent study in
mouse primary motor neurons and human iPSC-derived neurons
showed C9ORF72 regulates cytoskeletal actin dynamics through
phospho-coﬁlin and shRNA mediated knockdown of C9ORF72
leads to axon outgrowth deﬁcits (67). However, the absence of
C9ORF72 loss of function (LOF) mutations in patient populations
(28) along with rare C9ORF72 homozygous patients displaying a
comparable clinical proﬁle to heterozygous patients further argues
against haploinsufﬁciency as the primary mechanism of disease (20).
Pathological hallmarks of C9ORF72RE
One of the pathological signatures of C9ORF72RE mutation is the
presence of RNA foci in cerebellum, motor cortex, spinal cord and
hippocampus. These are expressed in both neurons and glial cells.
RNA foci are generated by bi-directional transcription of G4C2
repeat expansion (both sense and antisense) (2, 9, 12, 45). RNA
foci are also observed in cortical neurons, motor neurons, astrocytes
and oligodendrocytes derived from C9ORF72RE iPSCs (1, 16, 39,
44, 62). It is widely believed that G4C2 RNA foci sequesters RNA
binding proteins and thereby causes toxicity to neurons and glial
cells. A number of unbiased studies using co-localization and
immunoprecipitation have identiﬁed ribonucleoproteins, such as
hnRNPA1, hnRNPA2/B1, hnRNPA3, ADARB2, Pur-alpha, Ran-
GAP1 that are associated with RNA foci (10, 16, 48).
Albeit rare, hairpin formation of repeat expansion mutations can
trigger translation of the repeats through novel non-ATG initiated
(RAN) translation. Translation of such repeats are characterized in
other diseases such as CTG expansion in 30UTR of DMPK gene
causing myotonic dystrophy type 1 (DM1) (86), and (CTG)n
expansion in ATX8 gene lead to bidirectional expression of poly-Q
inclusions causing spinocerebellar ataxia type 8 (SCA8) (50). Simi-
larly, C9ORF72RE has been observed to be translated through an
unconventional mechanism of repeat associated non-ATG (RAN)
translation (2, 49). RAN translation from both sense and antisense
sequence leads to generation of ﬁve distinct di-peptide repeats
(DPR): poly-GA, poly-GP, poly-GR, poly-PR, poly-PA (47). These
DPR’s are associated with p621ve, ubiquitin1ve, TDP432ve cyto-
plasmic inclusions in both neurons and glia, a unique pathology of
C9ORF72RE post-mortem tissues (2, 49). Moreover, a recent trans-
genic mouse model of C9ORF72, where human C9ORF72 locus
containing repeat expansion mutation is inserted in mouse, shows
both RNA foci and DPRs in neurons and astrocytes thus recapitu-
lating the pathology observed in patients (54).
Toxic gain of function hypothesis
Expression of RNA foci and DPR’s in various disease models of
C9ORF72 suggests that toxic gain of function causes C9ORF72RE
mediated ALS. However, it is still debatable whether sequestering
ribonucleoproteins by RNA foci and/or DPR’s causes neurotoxic-
ity. Ectopic expression of G4C2 repeats in mouse primary neurons
recapitulated RNA foci and correlated with apoptosis (33). Adeno
viral mediated overexpression (G4C2)66 in mice resulted in expres-
sion of RNA foci, DPRs and p-TDP43 inclusions. Furthermore,
they were associated with loss of cortical neuron and signiﬁcant
motor deﬁcits (7). These studies suggest a toxic gain-of-function
mechanism of neurodegeneration. However, it is difﬁcult to tease
apart if RNA foci and/or DPR is causing neurotoxicity since
both are expressed. Overexpression of poly-PR DPR in an ATG-
dependent translation in mouse primary neurons and human
iPSC-derived motor neurons resulted in neurotoxicity as assayed
by longitudinal survival analysis (80). Another study shows ectopic
expression of poly-GA in mouse cortical neurons is associated with
reduced dendritic branching and increased caspase 3 mediated apo-
ptosis (42). The majority of these studies overexpress G4C2 repeats
in different models, however, they do not evaluate the consequence
of physiological expression of C9ORF72RE. Human iPSC model
systems addresses this issue. Some of the phenotypes observed in
C9ORF72 mutant motor neurons such as glutamate induced excito-
toxicity (16), hypoexcitability (62) are mitigated by antisense oligo-
nucleotide (ASO) treatment hinting that sequestering of
ribonucleoproteins by RNA foci is a driver for disease mechanism.
However, it is imperative to generate speciﬁc antibodies to inhibit
DPRs to identify if DPRs are also contributing to the disease
phenotype.
Spread of DPRs
Among the di-peptide repeats, poly(GA) is prone to aggregation
in-vitro and form cytoplasmic inclusions (6). Recently there has
been emerging interest in cell to cell transmission of DPR’s. Inter-
cellular DPR seeding and transmission has been observed between
neuron to neuron and neuron to glial cells (81, 85). Moreover,
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direct cell to cell interaction is not required for transmission noting
that conditioned media and exosomes fractions are sufﬁcient to
induce transmission. These studies are performed predominantly
using ectopic expression of DPRs under a strong promoter in vari-
ous cell lines and primary neurons. However, this could lead to
high expression and thus not representative of normal pathophysi-
ology. To overcome this problem, Westergard et al, performed sim-
ilar studies using co-culture of iPSC-derived C9ORF72 mutant
sMNs and GFP labelled wildtype MNs. They observed transmis-
sion of poly-GA, poly-GP and poly-GR DPRs thereby conﬁrming
its relevance at physiological levels (81). Further studies need to be
performed to see if DPRs are detected in cerebrospinal ﬂuid of
patients which could be potentially used as a biomarker and also
potentially an opportunity to neutralize pathogenic DPRs using
antibody therapy.
Cellular pathways that are disrupted in
C9ORF72RE mediated ALS
Nuclear cytoplasmic protein shuttling defects
In a quest to elucidate the molecular mechanism for pathogenicity
of hexanucleotide repeat expansion in C9ORF72, interactome and
modiﬁer studies revealed dysfunctional nuclear-cytoplasmic traf-
ﬁcking of both proteins and RNA. Zhang et al, identiﬁed RanGAP1,
a protein vital in shuttling of proteins containing nuclear localization
signal, interacting with the G4C2 RNA. Ran GAP1 overexpression
was reverted the ommatidial defects in the eye and restore locomo-
tion deﬁcits of Drosophila model expressing 30 G4C2 repeats.
iPSC-derived C9ORF72RE mutant motor neurons displayed misloc-
alization of RanGAP1 protein in cytoplasm and exhibited deﬁcits in
nuclear import of protein, which includes TDP43. Targeting the
RNA foci by anti-sense oligonucleotides (ASO) and facilitating
nuclear import with a compound KPT 276, an inhibitor of exportin,
reversed the phenotype observed in Drosophila model and human
neurons (84).
Another independent study undertook an unbiased loss of func-
tion (LOF) screen to identify genes that modify G4C2 hexanucleo-
tide repeat expansion mediated rough eye phenotype in Drosophila
model (21). Eighteen modiﬁers that target the nuclear pore complex
were identiﬁed. These included Nup50 and Nup153 RAN were
identiﬁed to enhance the rough eye phenotype. ALYREF, a RNA
binding protein responsible for RNA export, was identiﬁed to sup-
press rough eye phenotype. Consistent with these ﬁndings, iPSC-
derived C9ORF72RE motor neurons showed increased nuclear
RNA retention when compared with controls (21). These studies
show a toxic gain of function of either G4C2 RNA and DPRs alter
the nuclear-cytoplasmic transport and lead to pathogenicity.
Vulnerability to ER and oxidative stress
Endoplasmic reticulum (ER) is an organelle necessary for produc-
tion, folding and processing of secretory and transmembrane pro-
teins. ER homeostasis, a balance between protein load and capacity
to fold this load, is essential for proper folding and thus function of
proteins. ER homeostasis is known to be perturbed by accumula-
tion of misfolded mutant protein in the ER lumen. Recent studies
have shown evidence ER stress is perturbed in C9ORF72RE.
Daﬁnca et al, (11) showed that iPSC-derived C9ORF72RE motor
neurons exhibited elevated levels of Ca21 in ER with increased lev-
els of GRP78/BiP – a marker for UPR and ER stress response.
Another independent study showed that iPSC-derived C9ORF72RE
motor neurons are vulnerable to tunicamycin, inducer of ER stress,
in a dose dependent manner (26). These studies imply that protein
homeostasis is perturbed in C9ORF72RE motor neurons, however
causality for the ER stress remains unclear.
Oxidative stress is the result of an imbalance in the generation of
free radicals and ability of the cell to neutralize/scavenge. The
imbalance generally arises due to leakage of electrons from the
mitochondria respiratory chain. Many studies, aside from identiﬁca-
tion of mutation in super oxide dismutase gene (SOD1), have shown
evidence for increased oxidative stress in post mortem tissues
of ALS patients. Increased levels of 8-hydroxy-20-deoxyguanosine
(8-OHdG), a marker for oxidized DNA, was observed in spinal cord
ventral horn motor neurons (19). Recent study observed an age
dependent (in culture) increase in DNA damage as measured by
expression of gH2AX in iPSC-derived C9ORF72RE motor neurons
(40). Interestingly, ectopic expression of poly-GR80 but not
poly-GA80 induced oxidative stress in C9ORF72
RE motor neurons.
Treatment of mutant motor neurons with Trolox, Vitamin E analog,
marginally reduced oxidative stress suggesting oxidative stress may
also contribute to the disease mechanism (40).
Neuronal Excitability
Evidence for neuronal hyperexcitability has been broadly observed
across the genetic spectrum of ALS and has been suggested to
manifest pre-symptomatically before potentially contributing to the
degenerative process (3, 77). Emerging clinical functional data for
symptomatic ALS patients that carry the C9ORF72RE shows axonal
hyperexcitability in lower motor neurons (23) and the cortex (24,
65, 82). In direct contrast, cortical hyperexcitability has not been
observed in FTD and ALS-FTD patients, or asymptomatic patients,
carrying C9ORF72REs (65).
Neuronal excitability maybe inﬂuenced by intrinsic (isolated
neuronal ﬁring, functional receptor/ion channel expression) and/or
extrinsic (synaptic and extra-synaptic activity, connectivity) factors.
Mechanistic studies are required to elucidate the full contribution of
either to any potential excitability impairment in ALS. Electrophys-
iological approaches have therefore been applied to determine
whether such functional impairments manifest at single neuron,
synaptic and network levels in C9ORF72RE patient iPSC-derived
neurons.
Using multi-electrode arrays, Wainger et al, 2014 showed net-
work hyperexcitability in the form of increased basal spontaneous
spike ﬁring frequency in C9ORF72RE patient hiPSC-derived cul-
tures (14 days old, grown in co-culture with primary mouse cortical
astrocytes). Cultures in this study contained a low percentage
(<20%) of Islet11 motor neurons, but ultimately equivalent net-
work hyperexcitability was observed in enriched mutant SOD1
patient iPSC-derived HB91-GFP motor neuron cultures suggesting
a convergence of an ALS hyperexcitable phenotype in lower motor
neurons. Interestingly, patch-clamp electrophysiological recordings
from mutant SOD1 neurons determined a decreased functional
expression in delayed-rectiﬁer potassium channels, but not sodium
channels. Such channels have sustained activation kinetics and loss
of functional expression is mechanistically consistent with
increased capacity of neurons to ﬁre action potentials and display
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an increased network ﬁring frequency. Loss of functional expres-
sion of potassium channels with sustained kinetics is theoretically
predicted to be a component in the generation of the observed
hyperexcitability in symptomatic C9ORF72RE patient lower motor
neuron axons (23). Retigabine, a Kv 7 delayed-rectiﬁer potassium
channel family activator, has therefore been raised as a potential
therapeutic in ALS (78).
In direct contrast, Sareen et al demonstrate that C9ORF72RE
patient iPSC-derived neuronal cultures (66–79 days old) containing
SMI321 motor neurons (60% enrichment) show intrinsic hypo-
excitability with a decrease in the ability to ﬁre action potentials
in response to depolarization. Concurrently performed RNA-
sequencing indicated an increased expression of the delayed
rectiﬁer potassium channel, KCNQ3, which is mechanistically con-
sistent with increased intrinsic hypoexcitability (62).
These divergent ﬁndings appear to be reconciled by temporal
analysis of excitability of enriched MNs generated from
C9ORF72RE patient iPSCs using patch-clamp electrophysiology
(14). Evidence for intrinsic hyperexcitability was found at an early
time point (21–28 days) in culture in a subset of cells when classi-
ﬁed according to their ﬁring state. Recordings made from cells
maintained up to 70 days showed that cells lost the capacity to ﬁre
action potentials and accordingly lost functional expression of
sodium and potassium channel-mediated conductances.
Together this suggests for C9ORF72RE–mediated ALS that a
potential early intrinsic hyperexcitability potentially transitions,
with time, into a hypoexcitable phenotype in motor neurons.
However, the general contribution of intrinsic hyperexcitability to
ALS has been further challenged by studies where data from other
iPSC-derived motor neuron models of ALS (38, 53) and the mutant
SOD1 mouse (5, 13, 35) identify intrinsic hypoexcitability rather
than hyperexcitability as the key physiological phenotype. Indeed,
pharmacological interventions that increase excitability to improve
motor neuron function and survival have been proposed (53, 64).
Differences in neuronal excitability may also arise through
altered functional synaptic properties. Patch-clamp recordings from
C9ORF72RE patient iPSC-derived cultures containing motor neu-
rons are consistent with hypoexcitability where a reduced detection
of cells with post-synaptic events was observed after 7–10 weeks
in culture (14). Such data is consistent with synaptic loss/reduced
synaptic function observed in ALS patients and other models of
ALS (35, 53, 63, 84). The pathological loss of synaptic input is
supported by increasing evidence that RNA-seq-based studies on
C9ORF72RE iPSC-derived MN cultures and post mortem brain
samples that consistently indicate altered expression of synaptically
associated proteins (58, 62) and furthermore that C9ORF72 protein
is observed to accumulate at the synapse (69). No other functional
data is currently available that assesses synaptic physiology in
C9ORF72RE models.
Subtle but important differences in experimental approaches
likely accounts for the differences in excitability ﬁndings. These
include potential for variability in iPSC-derived cellular composi-
tion, including speciﬁc motor neuron identity, and maturation of
iPSC-derived cultures (for in-depth review (60)). For example,
motor neuron cultures obtained from different protocols may
include different levels of astrocytes that will also harbor
C9ORF72RE. C9ORF72RE-iPSC-derived astrocytes have previ-
ously been shown to be toxic to iPSC-derived motor neurons (44).
The contribution of iPSC-derived astrocytes to the observed
intrinsic excitability of C9ORF72RE-patient-derived neurons
remains unexplored. Furthermore, consideration of the culture com-
position has important implications for investigating synaptic phys-
iology – it is unknown to the extent to which the synaptic
connectivity in such cultures represents that of native circuits (60).
In this regard, altered intrinsic neuronal excitability may simply
reﬂect a homeostatic response to the extent of synaptic innervation
within the culture (43).
The current evidence for hyper- vs. hypo-excitability in ALS is
clearly heterogeneous. The volume of evidence from in vitro mod-
els of ALS is weighted towards hypoexcitability in C9ORF72RE
ALS, but this appears at clear odds with the existing hyperexcitabil-
ity data obtained from symptomatic ALS C9ORF72RE patients. To
move forward in understanding neuronal/circuit dysfunction in
C9ORF72RE-mediated ALS and FTD we must understand better
the physiological representation of the iPSC-derived neurons to
those of native populations. In alliance with this, longitudinal clini-
cal C9ORF72RE patient data must be obtained to verify and appro-
priately align observations made in iPSC-derived studies (25).
Excitotoxicity
Persistent glutamate-mediated excitotoxicity is thought to play an
important role in the progression of ALS including C9ORF72RE
patients (8, 76). The development of the excitotoxicity hypothesis
is multifaceted and has largely been developed from studies on
mutant SOD1 and post mortem studies. This includes (1) the reduc-
tion of astroglial glutamate transporter expression that acts to
reduce the clearance of synaptic glutamate; (2) an increase in func-
tional Ca21-permeable glutamate-gated AMPA receptor expression
upon motor neurons and (3) a potentially reduced intracellular buf-
fering Ca21-capacity leading to toxic elevations of intracellular
Ca21 (8, 76). It is thought that riluzole, the only licensed drug for
ALS, largely acts through multiple mechanisms to reduce excito-
toxicity (8). To date, only a few iPSC-based studies have provided
data to support the role of glutamate receptor-mediated excitotoxic-
ity in motor neurons.
Donnelly et al, 2013 demonstrated that cultures containing
C9ORF72RE patient iPSC-derived motor neurons (30%–40%
HB91) are highly susceptible to glutamate excitotoxicity, which is
blocked by pharmacological inhibition of AMPA receptors,
NMDA receptors and voltage-gated Ca21 channels. In association
with a reduction in RNA foci, treatment of motor neurons with
C9ORF72RE anti-sense oligonucleotides partially reduced the
vulnerability to excitotoxicity suggesting the glutamate-mediated
excitotoxicity is associated with RNA toxicity. Interestingly, this
study also observed nuclear co-localization of ADAR2B2 RNA
with RNA foci. This enzyme controls the post-transcriptional modi-
ﬁcation of the GluA2 subunits (glutamine to arginine) that imparts
Ca21-impermeability to GluA2-containing AMPA receptors.
Previously inefﬁcient editing of the GluA2 subunit has been impli-
cated shown in the post mortem spinal cord of sporadic ALS
patients (32). The link between Ca21-permeable AMPA receptor-
mediated excitotoxicity in ALS and C9ORF72RE remains to be
deﬁnitively determined.
In contrast, cortical neurons derived from C9ORF72RE FTD
patients show altered AMPAR transcript regulation that is consist-
ent with more functional Ca21-impermeable AMPA receptors (22).
Furthermore, the functional AMPA receptor composition in
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oligodendrocytes derived from C9ORF72RE ALS patient iPSCs is
predominantly Ca21-impermeable (39). These data indicate that
excitotoxicity in these cell types is highly unlikely to be mediated
via altered AMPA receptor composition. Importantly, this data is
suggestive of both region and cell-type speciﬁc C9ORF72RE-medi-
ated pathology.
Glial Cross-Talk
It is well recognized that non-neuronal cellular phenotypes are
likely to inﬂuence ALS/FTD disease progression beyond that of
the astrocytic contribution to glutamate-mediated excitotoxicity
(29). Meyer et al, 2014 demonstrated that C9ORF72RE-derived
astrocytes were toxic to iPSC-derived HB91 motor neurons.
Importantly, equivalent experiments using mutant SOD1 (human
or rodent) derived astrocytes demonstrate a similar feature (15, 27,
41). Mutant TDP-43 iPSC-derived astrocytes appear not to be
associated with toxicity to motor neurons (66) although mutant
astrocytes in a TDP-43 rat model do adversely inﬂuence motor neu-
ron survival (75). It therefore remains unclear if astrocytes in ALS
generally have an associated toxicity to motor neurons.
Recently, oligodendrocyte abnormalities have also been identi-
ﬁed in experimental models and pathological studies of ALS (30).
Rodent mutant SOD1 oligodendrocytes have impairments in
differentiation from progenitor cells leading to insufﬁcient re-
myelination of motor neurons and those that differentiate appear to
exhibit morphological abnormalities consistent with impairments in
maturation (30, 56). Mutant SOD1 oligodendrocytes that myelinate
appear less able to metabolically support motor neuron axons (34).
Furthermore, co-cultures of mutant SOD1 patient iPSC-derived oli-
godendrocytes were shown to impart toxicity to motor neurons
(18). However, data emerging from C9ORF72RE patient iPSC-
derived oligodendrocyte studies are highly divergent with mutant
SOD1 studies. Despite presenting pathological signatures of
C9ORF72RE-mediated disease, including RNA foci, C9ORF72RE
patient iPSC-derived oligodendrocytes were shown not to impart
toxicity to motor neurons when maintained in co-culture (18) and
furthermore were not associated with any maturational or morpho-
logical impairment (39).
The analysis of factors (contact and conditioned media) regulat-
ing glial toxicity to motor neurons remains to be addressed
although early studies have identiﬁed promising potential therapeu-
tic candidates (70). Moreover, the very recent ability to generate
functional microglia from human pluripotent cultures is of great
interest for ALS especially for C9ORF72RE-mediated disease that
is maximally expressed in microglia (51, 55).
SUMMARY
iPSC technology allows the generation of multiple in vitro cellular
types that are relevant to modeling C9ORF72RE-mediated disease.
Critically, patient-derived material largely recapitulates major
C9ORF72RE pathology and beyond this has been used to uncover
new potential disease hypotheses. Data from a range of
C9ORF72RE models will ultimately be required to reinforce these
ideas. In this regard, it is important to fully understand the nature of
the iPSC-derived material and how it reﬂects that of native in vivo
disease progression to place such results into appropriate context.
Nonetheless iPSC technology will continue to be an important
platform to explore C9ORF72RE-mediated disease. The increasing
ability of these systems to be adapted and scaled for high-
throughput screening for novel pharmacological compounds is of
particular promise.
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